References
- Byrd J C, Rai K, Peterson B L, Appelbaum F R, Morrison V A, Kolitz J E, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49–53
- Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro A J, et al. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62: 873–882
- Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
- Moreton P, Kennedy B, Lucas G, Leach M, Rassam S M, Haynes A, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971–2979
- Hillmen P H, Skotnicki A S, Robak T R, Jaksic B J, Sirard C S, Mayer J M. Progression free survival (PFS) is superior with alemtuzumab (Campath®, Mabcampath®] vs chlorambucil as front-line therapy for patients with B-cell Chronic Lymphocytic Leukemia (BCLL). Haematologica 2007; 92(Suppl 1)0127a
- Lozanski G, Heerema N A, Flinn I W, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278–3281
- Osuji N C, Del Giudice I, Matutes E, Wotherspoon A C, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005; 90: 1435–1436
- Turgut B, Vural O, Pala F S, Pamuk G E, Ğlu K T, Demir M, et al. 17p deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma 2007; 48: 311–320
- Gandhi V. p53 as a predictor for chemotherapy response in CLL cells. Leuk Lymphoma 2007; 48: 219–220
- Tam C S, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma. 2007; 1931–1939
- Chanan-Khan A, Miller K C, Musial L, Lawrence D, Padmanabhan S, Takeshita K, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343–5349
- Byrd J C, Lin T S, Dalton J T, Wu D, Phelps M A, Fischer B, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109: 399–404
- Thornton P D, Matutes E, Bosanquet A G, Lakhani A K, Grech H, Ropner J E, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82: 759–765
- Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G, et al. Chronic Leukemia Working Party of the EBMT. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005; 19: 1029–1033
- Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, et al. Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12–17
- Brown J R, Kim H T, Li S, Stephans K, Fisher D C, Cutler C, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2006; 12: 1056–1064
- Khouri I F, Saliba R M, Admirand J, O'Brien S, Lee M S, Korbling M, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007; 137: 355–363
- Oscier D G, Wade R, Orchard J, Davis Z, Best G, Morilla A, et al. Prognostic factors in the UK LRF CLL4 trial. Blood 2006; 108: 92a, abstract 299